Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(2S)-a-Methylglutamic acid
Discontinued Product
0809 has been discontinued.
View all Non-selective Metabotropic Glutamate products.
说明： Not fully characterised
生物活性 for (2S)-a-Methylglutamic acid
Reported to show agonist activity at mGlu receptors; full spectrum of activity awaits characterisation.
技术数据 for (2S)-a-Methylglutamic acid
| 分子量 | 161.16 |
| 储存 | Store at RT |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for (2S)-a-Methylglutamic acid
分析证书目前不在网上提供。
请联系客户服务
请联系客户服务
参考文献 for (2S)-a-Methylglutamic acid
参考文献是支持产品生物活性的出版物。
Kemp et al (1996) Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices. Eur.J.Pharmacol. 309 79 PMID: 8864697
关键词: (2S)-a-Methylglutamic acid, (2S)-a-Methylglutamic acid supplier, Non-selective, mGlu, 0809, Tocris Bioscience
(2S)-a-Methylglutamic acid 的评论
目前没有该产品的评论。 Be the first to review (2S)-a-Methylglutamic acid and earn rewards!
Have you used (2S)-a-Methylglutamic acid?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.